The drug
Digitalis, an extract of
Digitalis purpurea, Foxglove plant, is in use since long. Medical practitioners, namely, William Withering, 1785 [
1] and Hahnemann, 1803 [
2], had introduced the drug in their respective systems of medicine. Out of about thirty known organic compounds of
Digitalis purpurea only 4–6 are medicinally active components comprising of Digoxin,
Digitoxigenin,
Digoxigenin, and
Saponins.
Digitalis purpurea derivatives are used in treatment of diseases like heart failure, arrhythmia, neurological diseases and also being tried as antitumor [
3].
Digoxin (C
41H
64O
14) is 300 times more potent than the powder prepared from
Digitalis purpurea. It has a molecular weight of 780.95, and the absolute bioavailability of Digoxin intravenous injection is 100%. Time of onset of the effect of Digoxin after intra-venous injection is 5–30 minutes, Patients maintained on Digoxin may also use ultradiluted preparations of the same, ultimately increasing the body burden of Digoxin. Saturated extract of an aqueous ethanol mixture is used to prepare serial dilution of the drug
Digitalis purpurea and is represented by the suffix “
θ”. Serial dilutions also are referred to as potencies “1c” or “1” in centesimal scale, which means that one part of the “
θ” saturated extract of the drug is mixed to make 100 parts of aqueous ethanol mixture and succused. When the same process is repeated 6 times, by adding 1 part of the previous potency in 99 parts of aqueous ethanol mixture and succused, after each stage starting from the first dilution for the next 5 times, “6c” or “6” potency is obtained. Presently, it is not possible to detect the serially ultradiluted drug
Digitalis purpurea in biological samples. However, attempts are on to find the “evidence base” of serially ultradiluted drugs. Methods to identify the medicinally active ingredient in ultradiluted drugs have been attempted sparingly [
4]. The investigation of homeopathic drugs is extremely interesting and challenging and from that point of view shows novelty.
Digitalis purpurea is readily available commercially, in serial dilutions prepared with aqueous alcohol (91.4%) as diluent. The serial dilution 12c of the drug, at a ratio 10
−24, has a 60% probability of containing one molecule of original material if one mole of the original substance was used. Digitalis-like toxicity (
Digitalis intoxication) results from an overdose of the drug, consumption of
Digitalis purpurea plant products, and from toad skin (another animal source: butterflies) [
5].
Digitalis intoxication causes anorexia, nausea, vomiting, and diarrhea, jaundiced or yellow vision, appearance of blurred outlines, reduced heart rate, and weight loss. It is also necessary to evaluate the quality of the drug in solutions/dilutions. This motivated us and necessitated detection of
Digitalis purpurea in serial dilutions. Attempts had been made to detect Digoxin in solutions by various methods [
6].
The primary aim of this work is to detect the presence of Digitalis purpurea (DP), Digoxin, and/or Digoxin-like substance in serial ultradilutions using fluorescence spectroscopy and cyclic voltametry for comparison of the components of Digitalis purpurea, which has intrinsic fluorescence.
This original research work offers additional data for improving standardization of ultradiluted drugs in complementary/alternative system of medicine. Two analytical methods, fluorescence spectroscopy and cyclic voltametry (CV), of the ultradiluted drugs
Digitalis purpurea vis-à-vis Digoxin (0.25

mg/mL) were carried out for detection of the Digoxin-like substance.
The methods reported here are highly selective, sensitive, stable, and reproducible. The structure of medicinally active ingredient Digoxin is given in . The compound is known to be hydrophobic in nature, but the sugar moiety attached to the compound changes its solubility. It is found to be somewhat soluble in chloroform in its purest form.